A digenic human immunodeficiency characterized by *IFNAR1* and *IFNGR2* mutations

Rodrigo Hoyos-Bachiloglu, …, Mofareh AlZahrani, Raif S. Geha


Primary immunodeficiencies are often monogenic disorders characterized by vulnerability to specific infectious pathogens. Here, we performed whole-exome sequencing of a patient with disseminated *Mycobacterium abscessus, Streptococcus viridians* bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that regulate distinct IFN pathways. The patient had a homozygous frameshift deletion in *IFNGR2*, which encodes the signal transducing chain of the IFN-γ receptor, that resulted in minimal protein expression and abolished downstream signaling. The patient also harbored a homozygous deletion in *IFNAR1* (*IFNAR1*^{557Gluext*46}), which encodes the IFN-α receptor signaling subunit. The *IFNAR1*^{557Gluext*46} resulted in replacement of the stop codon with 46 additional codons at the C-terminus. The level of IFNAR1^{557Gluext*46} mutant protein expressed in patient fibroblasts was comparable to levels of WT IFNAR1 in control fibroblasts. IFN-α–induced signaling was impaired in the patient fibroblasts, as evidenced by decreased STAT1/STAT2 phosphorylation, nuclear translocation of STAT1, and expression of IFN-α–stimulated genes critical for CMV immunity. Pretreatment with IFN-α failed to suppress CMV protein expression in patient fibroblasts, whereas expression of WT IFNAR1 restored IFN-α–mediated suppression of CMV. This study identifies a human *IFNAR1* mutation and describes a digenic immunodeficiency specific to type I and type II IFNs.

Find the latest version:

https://jci.me/93486/pdf
A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations


1Division of Immunology, Boston Children’s Hospital and Department of Pediatrics, and 2Department of Microbiology and Immunobiology and Harvard Program in Virology, Harvard Medical School, Boston, Massachusetts, USA. 3Department of Pediatrics, King Fahad Medical City, Riyadh, Saudi Arabia.

Primary immunodeficiencies are often monogenic disorders characterized by vulnerability to specific infectious pathogens. Here, we performed whole-exome sequencing of a patient with disseminated Mycobacterium abscessus, Streptococcus viridans bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that regulate distinct IFN pathways. The patient had a homozygous frameshift deletion in IFNGR2, which encodes the signal transducing chain of the IFN-γ receptor, that resulted in minimal protein expression and abolished downstream signaling. The patient also harbored a homozygous deletion in IFNAR1*557Gluext*46, which encodes the IFN-α receptor signaling subunit. The IFNAR1*557Gluext*46 resulted in replacement of the stop codon with 46 additional codons at the C-terminus. The level of IFNAR1*557Gluext*46 mutant protein expressed in patient fibroblasts was comparable to levels of WT IFNAR1 in control fibroblasts. IFN-α-induced signaling was impaired in the patient fibroblasts, as evidenced by decreased STAT1/STAT2 phosphorylation, nuclear translocation of STAT1, and expression of IFN-α–stimulated genes critical for CMV immunity. Pretreatment with IFN-α failed to suppress CMV protein expression in patient fibroblasts, whereas expression of WT IFNAR1 restored IFN-α–mediated suppression of CMV. This study identifies a human IFNAR1 mutation and describes a digenic immunodeficiency specific to type I and type II IFNs.

Introduction

A paradigm of host immunity is that an individual’s susceptibility to pathogens indicates a specific molecular defect. Yet, there are apparent exceptions to this paradigm: individuals who develop infections from a spectrum of organisms either broader or narrower than that predicted by the identified molecular defect. Several cases of human mutations affecting the interferon (IFN) pathways exemplify such exceptions. There are 3 families of IFNs: type I (IFN-α, IFN-β, and IFN-ω), type II (IFN-γ), and type III (IFN-λ1, IFN-λ2, and IFN-λ3) (1). Each IFN family has its specific receptor (IFNAR, IFNGR, IFNLR, respectively) and unique signaling pathways, although crosstalk occurs among these pathways (1). Type I IFNs induce the expression of MHC class I and stimulate NK cell– and CD8+ T cell–mediated cytotoxicity to promote the killing of cells infected with virus (1). Only 2 types of defects in the type I IFN pathway have been reported to date: one kindred with a truncation mutation in IFNAR2 and patients deficient in STAT2, a transcription factor downstream of IFNAR activation (2–4). These patients presented with disseminated live vaccine–strain viral infections, indicating the contribution of IFNAR signaling to the induction of IFN-stimulated genes (ISGs) important for inhibiting viral replication and infection (2–4). However, despite the known importance of type I IFNs in controlling viral pathogens, both the IFNAR2- and STAT2-deficient patients had either absent or mild symptoms after infection with childhood viruses, including cytomegalovirus (CMV), Epstein-Barr virus, varicella zoster virus (VZV), and respiratory viruses (2, 3). This suggests that the type I IFNs have an essential, but narrow, role in host immunity against viral pathogens.

The contributions of the type II IFN pathway to host immunity have been illustrated in patients with mutations in the genes encoding the IFNGR, 2 downstream transcription factors (STAT1 and IRF8), and the proteins important for IFN-γ secretion, such as IL-12, IL-12R, and ISG15 (5, 6). Due to the role of IFN-γ in macrophage activation, these patients are susceptible to intracellular organisms, most commonly mycobacteria and Salmonella, but also Listeria monocytogenes and Nocardia (5, 7). A few patients have been reported to have concomitant infections with additional pathogens, including CMV, respiratory syncytial virus, VZV, klebsiella, histoplasmosis, and paracoccidioidomycosis (7–10). It is not known if these atypical infections resulted from differences in environmental exposures or additional mutations affecting other mechanisms of host immunity.

We present a patient with disseminated mycobacteria, Streptococcus viridans bacteremia, and CMV viremia. We identified, for the first time to our knowledge, a digenic innate primary immunodeficiency leading to defective type I and type II IFN signaling that illustrates the diverse contributions of these pathways to host defense against specific pathogens.

Authorship note: R. Hoyos-Bachiloglu, J. Chou, and C.N. Sodoski contributed equally to this work. D.M. Knipe, M. AlZahrani, and R.S. Geha contributed equally to this work.

Conflict of Interest: The authors have declared that no conflict of interest exists.

Submitted: February 17, 2017; Accepted: September 14, 2017.

Results and Discussion

The proband is the only child of consanguineous Saudi Arabian parents (Figure 1A). He was healthy until 2 months of age, when he developed a high fever and a blood culture positive for *Streptococcus viridans*, and severe CMV viremia (4,000,000 copies/ml). Within a few days, he developed anemia, thrombocytopenia, splenomegaly, and lymphadenopathy. He had laboratory findings consistent with hemophagocytic lymphohistiocytosis (HLH): elevated ferritin (4,000 μg/l), increased triglycerides (7.5 mmol/l), high soluble CD25 (6,500 U/ml), and hemophagocytosis in his bone marrow. His bone marrow was positive for *Mycobacterium abscessus* and CMV. His laboratory evaluation revealed elevated numbers of white blood cells and total lymphocytes, a mildly decreased CD4+ T-cell count, and increased numbers of CD8+ T cells (Table 1). His HIV PCR was negative. Targeted Sanger sequencing identified no mutations in genes associated with familial HLH (*PRF1, UNC13D, STX11, STXB1*). He was treated with dexamethasone and cyclosporine for HLH, gancyclovir for the CMV viremia, and isoniazid, rifampin, clarithromycin, ciprofloxacin, and amikacin for his mycobacterial infection. He recovered from this episode and has been treated with prophylactic antimycobacterial medications without any subsequent significant infections. He has received attenuated measles, mumps, and rubella virus vaccines without adverse sequelae. Due to his history of disseminated infections, the proband is now scheduled to undergo a hematopoietic stem cell transplant.

The proband’s consanguineous ancestry suggested an autosomal recessive immunodeficiency (Figure 1A). Whole-exome sequencing (WES) of the proband identified 2 potentially novel variants affecting distinct IFN pathways, in addition to 13 rare homozygous variants (Supplemental Table 1; supplemental mate-
The Journal of Clinical Investigation

CONCISE COMMUNICATION

The first is a homozygous single nucleotide deletion in IFNGR2 (IFNGR2C266fs, NM_005534: c.798delT: p.C266fs), which encodes the IFNGR signal transducing chain. Sanger sequencing of genomic DNA confirmed that the mutation was homozygous in the proband and heterozygous in his parents (Supplemental Figure 2A). The IFNAR1*557Gluext*46 mutation is predicted to replace the gene’s stop codon with 46 novel C-terminal codons, which was confirmed by Sanger sequencing of cDNA from the patient’s fibroblasts (Figure 2A and Supplemental Figure 2B). The additional C-terminal amino acids were predicted to add 5 kDa to the protein’s molecular weight. Immunoblotting of fibroblast lysates from the patient using an antibody directed against residues 450–500 revealed protein expression of IFNAR1*557Gluext*46 at a level comparable with that of WT IFNAR1 in control fibroblasts (Figure 2B). The small difference in molecular weight between WT IFNAR1 (30 kDa) and IFNAR1*557Gluext*46 (35 kDa) was not evident on immunoblotting due to the relatively high molecular weight of both proteins. IFNAR1 serves as the signaling chain of the IFNAR and is required for responsiveness to type I IFNs (1, 12). Binding of IFN-α to the IFNAR complex leads to the phosphorylation of STAT1 and STAT2 followed by assembly of the p-STAT1/p-STAT2 heterodimer. The p-STAT1/p-STAT2 heterodimer is released from the IFNAR complex, translocates to the nucleus, and induces expression of ISGs necessary for controlling viral replication and spread (12). IFN-α stimulation of the patient’s fibroblasts resulted in significantly decreased STAT1 and STAT2 phosphorylation compared with control fibroblasts (Figure 2C and D). Additionally, the nuclear translocation of p-STAT1 was significantly impaired in the patient’s fibroblasts 8 and 24 hours after IFN-α stimulation (Figure 2E). Although the mutant IFNAR1*557Gluext*46 protein retains the docking sites required for downstream intracellular signaling events, these results indicated that the addition of the potentially novel 46 amino acids partially disrupts the receptor’s downstream signaling. Unlike the IFNAR2- or STAT2-deficient patients, who developed fatal vaccine strain measles encephalopathy (2, 3), our proband had no complications after MMR vaccination. The residual signaling and ISG expression downstream of IFNAR1*557Gluext*46 in our proband may have been sufficient for providing immunity against attenuated, but not WT viruses.

We next assessed the antiviral state induced by IFN-α stimulation of patient and control fibroblasts. Since fibroblasts do not secrete IFN-γ, a cytokine produced exclusively by hematopoietic cells (13), we used patient-derived fibroblasts to specifically determine the impact of the IFNAR1*557Gluext*46 mutant protein on the induction of ISGs and CMV susceptibility independent of IFN-γ. IFN-α stimulation resulted in significantly impaired induction of IRF7, a transcription factor upregulated by activation of the IFNAR, as well as IFIT1 and IFIT2, two ISGs regulated by type I IFNs (12).

Table 1. Laboratory evaluation of the patient

<table>
<thead>
<tr>
<th>Hemoglobin, g/dl</th>
<th>9.6 (10.2–12.7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBCs, cells/μl</td>
<td>38,000 (8,400–13,700)</td>
</tr>
<tr>
<td>Neutrophils, cells/μl</td>
<td>9,660 (2,200–6,400)</td>
</tr>
<tr>
<td>Lymphocytes, cells/μl</td>
<td>8,770 (2,330–5,500)</td>
</tr>
<tr>
<td>Monocytes, cells/μl</td>
<td>855 (300–2,700)</td>
</tr>
<tr>
<td>Platelets, cells/μl</td>
<td>21,500 (221,000–471,000)</td>
</tr>
</tbody>
</table>

**Lymphocytes (normal range)**

| CD3+, cells/μl | 5.250 (2,500–5,500) |
| CD3*CD4*, cells/μl | 1,180 (1,600–4,000) |
| CD3*CD8*, cells/μl | 3,610 (560–1,700) |
| CD4*, cells/μl | 2,390 (300–2,000) |
| CD19*HLA-DR+ (%) | 100% |
| CD16+/CD56+, cells/μl | 1,100 (170–1,100) |

**Immunoglobulins (normal range)**

| IgG, mg/dl | 670 (20–601) |
| IgA, mg/dl | 40 (2.8–47) |
| IgM, mg/dl | 90 (17–105) |

**Lymphocyte proliferation (% of control)**

| Phytohaemagglutinin | 76 |
| Pokeweed | 143 |

**Neutrophil function**

| Dihydrorhodamine | Normal |

*A*Values outside the normal range are italicized and bolded.
to the CMV susceptibility seen in the patient’s cells, we examined whether the expression of WT IFNAR1 in the patient’s cells would restore the ability to control CMV infection. Patient and control fibroblasts were transduced with lentivirus containing either empty vector (EV) or IFNAR1, then treated with IFN-α for 17 hours, and subsequently infected with HCMV for 6 hours. The introduction of WT IFNAR1 had no effect on the residual CMV IE1 or IE2 expression in control fibroblasts pretreated with IFN-α (Figure 3C). In contrast, introduction of WT IFNAR1 reduced CMV IE1 and IE2 expression to 15%, which is significantly less than the 40% residual expression observed in EV-transduced patient cells (Figure 3C). Notably, the expression of WT IFNAR1 in patient cells restored IFN-α–mediated suppression of CMV IE1 and IE2 expression to a level comparable to that observed in control IFN-α–treated cells (Figure 3C). Collectively, these results demonstrated that the impaired signaling downstream of IFNAR1*557Gluext*46 is insufficient for controlling CMV protein expression.
The unbiased approach inherent in next-generation sequencing has shown that approximately 5% of sequenced patients have disease-causing multiloci variants (14). Multigenic mutations have been shown to shape the phenotype of patients with autoimmunity, severe congenital neutropenia, and familial HLH (15–17). This is the first report, to our knowledge, of a digenic human primary immunodeficiency caused by defects specific to IFNAR1 and IFN-GR2. This is unique from previously published reports of patients with selective susceptibility to mycobacteria and viruses due to mutations in genes encoding proteins important for signaling via multiple IFNs and other cytokines. These include STAT1, TYK-2, and NEMO, all of which are downstream of all 3 types of IFNs as well as multiple cytokines. IL-27 signals via STAT1, IL-6 and IL-12 signal via TYK2, and multiple cytokines signal through the NEMO-dependent NF-κB classical pathway (7). Therefore, our patient’s susceptibility to multiple types of pathogens, specifically mycobacteria, extracellular bacteria, and CMV, illustrates the specific contributions of the IFNAR and IFNGR to host immunity in vivo.

Our patient had disseminated CMV characterized by an exceptionally high viral load, a striking phenotype not seen in a previously reported IFNAR2-deficient patient (2). We have shown an essential contribution of IFNAR1 signaling to IFN-α-mediated control of HCMV IE1 and IE2 protein expression. In addition, our patient’s mutation in IFNGR2 abrogates the contribution of IFN-γ to host defense against CMV. IFNGR2 and IFNAR1 form heterodimers (18). The binding of IFN-γ to IFNGR2/IFNAR1 heterodimers results in IFNAR1 phosphorylation, STAT1/STAT2 recruitment to the IFNAR1 subunit of the heterodimer, and ultimately, assembly of ISG factor 3 (ISGF3) for inhibition of viral activity (18). Additionally, IFN-γ induces ISGs through activation of IFNGR2/IFNAR1 heterodimers on the caveolar membrane (18). The importance of IFNAR/IFNGR double-knockout mice, which are more susceptible
to lymphocytic choriomeningitis virus than either the IFNR or IFN-GR single-knockout mice (19). Both type I and II IFNs are important for upregulating the phagosomal proteins critical for defense against extracellular bacteria (20, 21). The dual defect in type I and II IFNs in our patient may have contributed to the disseminated infection with Streptococcus viridans, a weakly virulent, extracellular organism. The proband’s history of disseminated infections with opportunistic pathogens underscores his need for curative therapy. Although drugs that enable translational read-through of nonsense mutations have been used to treat cystic fibrosis and muscular dystrophy, this approach cannot correct defects caused by frameshift mutations. Hematopoietic stem cell transplant is the only cure at this time for this digenic disease.

Primary immunodeficiencies have been classically considered monogenic diseases, but WES/whole-genome sequencing has begun to identify phenotypes shaped by multiple mutations (15, 22, 23). This study demonstrates how a disease previously ascribed to a monogenic cause may arise from potentially novel multigenic mutations, indicating the utility of an unbiased approach for variant identification. Cases with atypical phenotypes studied before the widespread use of WES may thus have had secondary, unknown pathogenic mutations. Additionally, this study illustrates the burden of proof needed to determine the effect of novel secondary mutations, because the IFNAR1*Glu211Val*Glu214 Val* mutant allele retained all of the protein’s coding amino acids and protein expression, but led to impaired downstream signaling and defective inhibition of viral replication. The dissociation of predictable genotype-phenotype relationships and the approaches needed to prove new mechanisms of disease will define the practice of genomic medicine.

Methods

The full description of methods is in the supplemental material.

Statistics. All data are presented as mean ± SEM. Unpaired Student’s t test for single comparisons or 2-way ANOVA were used for multiple comparisons. P less than 0.05 was considered significant.

Study approval. The study was approved by the Boston Children’s Hospital Institutional Review Board. Written informed consent was obtained from all participants.

Author contributions

RHB, JC, CNS, AB, WB, and M. Angelova performed experiments. EAI, MKH, HAA, FA, MAS, NE, MAE, and M. AlZahrani provided clinical data and gave critical advice. RHB, JC, DMK, M. AlZahrani, and RSG designed and coordinated the investigations. RHB, JC, DMK, and RSG wrote the manuscript. The final version of the manuscript was approved by all authors.

Acknowledgments

This work was supported by National Institutes of Health grants P01AI-076210 and R21-AI24101 (to RSG), AI-106934 (to DMK), and K08AI116979-01 (to JC); a grant from the Perkin Fund (to RSG); a Jeffrey Modell Translational Research Award (to JC); and the Chilean Ministry of Education by the CONICYT PAI/INDUSTRIA 79090016 (to RHB).

Address correspondence to: Raif S. Geha, Division of Immunology, Boston Children’s Hospital, Karp Building, One Blackfan Circle, Boston, Massachusetts 02115, USA. Phone: 617.919.2482; Email: raif.geha@childrens.harvard.edu.